title: Aspirin 300 mg/day is effective for treating aspirin-exacerbated respiratory disease.
abstract: BACKGROUND
  Aspirin desensitization (AD) treatment at doses of up to 1300 mg/day improves outcomes in aspirin-exacerbated respiratory disease (AERD). The aim of this study was to investigate the efficacy of aspirin 300 mg/day in the treatment of patients with AERD.
  
  
  METHODS
  The study included 40 patients diagnosed in our clinic as AERD that were desensitized and treated with aspirin 300 mg/day between December 2005 and December 2012. Changes from the baseline status were analyzed at 1 year and at 3 years of follow-up.
  
  
  RESULTS
  Of the 40 patients included, 24 (60%) were female and median (interquartile range [IQR]) age was 45 (40-51) years. Median (IQR) duration of AD was 31.5 (10.5-48.5) months. In total, 29 patients continued treatment for at least 1 year and 18 patients for at least 3 years. The annual rate of use of systemic corticosteroid regimens, episodes of sinusitis, and surgery was significantly lower both at 1 year (P = 0.002, P = 0.01, and P < 0.001, respectively) and at 3 years (P = 0.001, P = 0.03, and P = 0.002, respectively). Significant improvement was observed in the nasal congestion score (P = 0.01) and sense of smell score (P = 0.05) at 1 year and in the postnasal drainage score (P = 0.01) at 3 years.
  
  
  CONCLUSIONS
  Daily treatment with aspirin 300 mg had beneficial effects in patients with AERD, especially for the control of upper airway disease.
authors.affiliation: Division of Immunology and Allergy, Department of Chest Diseases, School of Medicine, Hacettepe University, Ankara, Turkey.
authors.forename: S
authors.initials: S
authors.lastname: Comert
authors.forename: E
authors.initials: E
authors.lastname: Celebioglu
authors.forename: T
authors.initials: T
authors.lastname: Yucel
authors.forename: T
authors.initials: T
authors.lastname: Erdogan
authors.forename: G
authors.initials: G
authors.lastname: Karakaya
authors.forename: M
authors.initials: M
authors.lastname: Onerci
authors.forename: A F
authors.initials: AF
authors.lastname: Kalyoncu
mesh_terms: D000328:Adult; D001241:Aspirin / Q000008:administration & dosage* / Q000009:adverse effects*; D001249:Asthma / Q000139:chemically induced / Q000188:drug therapy; D055963:Asthma, Aspirin-Induced / Q000188:drug therapy*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged
chemical_list: D001241:Aspirin
keywords: aspirin desensitization treatment; asthma; desensitization; rhinitis